We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment.
- Authors
Alcon, Clara; Martín, Fernando; Prada, Estela; Mora, Jaume; Soriano, Aroa; Guillén, Gabriela; Gallego, Soledad; Roma, Josep; Samitier, Josep; Villanueva, Alberto; Montero, Joan
- Abstract
Targeted agents have emerged as promising molecules for cancer treatment, but most of them fail to achieve complete tumor regression or attain durable remissions due to tumor adaptations. We used dynamic BH3 profiling to identify targeted agents effectiveness and anti-apoptotic adaptations upon targeted treatment in rhabdomyosarcoma. We focused on studying the use of BH3 mimetics to specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance to therapy and prevent relapse. We observed that the MEK1/2 inhibitor trametinib rapidly depleted the pro-apoptotic protein NOXA, thus increasing MCL-1 availability. Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo. In conclusion, our findings indicate that the combination of a BH3 mimetic targeting MCL-1 with trametinib improves efficiency on rhabdomyosarcoma by blocking tumor adaptation to treatment.
- Subjects
RHABDOMYOSARCOMA; BCL-2 proteins; TUMOR treatment; CANCER treatment
- Publication
Cell Death Discovery, 2022, Vol 8, Issue 1, p1
- ISSN
2058-7716
- Publication type
Article
- DOI
10.1038/s41420-022-00959-w